In previous studies, abnormal MEK/ERK signaling has been reported in several types of carcinoma [172], and cell proliferation, metastasis, and drug resistance have been reported to be associated with the MEK/ERK signaling pathway [173,174]. Here, MAP2K7 is linked to carcinoma.